aminolevulinic acid has been researched along with Sarcopenia in 2 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Sarcopenia: Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although this study suggests safe administration and the possibility of ALA improving hand grip strength in patients with sarcopenia, further investigation is required." | 7.30 | Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| " This study aimed to assess the efficacy and dose dependency of ALA combined with iron in sarcopenia by measuring skeletal muscle mass index (SMI)." | 7.30 | Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| "Sarcopenia is a geriatric syndrome characterized by decreased physical performance, muscle mass, and strength." | 7.30 | Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| "Recently, sarcopenia has attracted attention as therapeutic target because it constitutes a risk factor for metabolic and cardiovascular diseases." | 5.46 | Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid. ( Endo, S; Fujii, C; Fujii, K; Hagiwara, A; Inoue, H; Itoh, H; Kawai, T; Mitsuishi, M; Miyashita, K; Muraki, A; Nakajima, M; Ryuzaki, M; Sato, M; Tamaki, M; Tanaka, T; Uto, A, 2017) |
| " Although this study suggests safe administration and the possibility of ALA improving hand grip strength in patients with sarcopenia, further investigation is required." | 3.30 | Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| " This study aimed to assess the efficacy and dose dependency of ALA combined with iron in sarcopenia by measuring skeletal muscle mass index (SMI)." | 3.30 | Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| "Sarcopenia is a geriatric syndrome characterized by decreased physical performance, muscle mass, and strength." | 3.30 | Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). ( Abe, Y; Hiyoshi, T; Inoue, I; Kaga, H; Kuribayashi, N; Seino, H; Tamura, Y; Watada, H; Yoshii, H, 2023) |
| "Recently, sarcopenia has attracted attention as therapeutic target because it constitutes a risk factor for metabolic and cardiovascular diseases." | 1.46 | Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid. ( Endo, S; Fujii, C; Fujii, K; Hagiwara, A; Inoue, H; Itoh, H; Kawai, T; Mitsuishi, M; Miyashita, K; Muraki, A; Nakajima, M; Ryuzaki, M; Sato, M; Tamaki, M; Tanaka, T; Uto, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tamura, Y | 1 |
| Kaga, H | 1 |
| Abe, Y | 1 |
| Yoshii, H | 1 |
| Seino, H | 1 |
| Hiyoshi, T | 1 |
| Kuribayashi, N | 1 |
| Inoue, I | 1 |
| Watada, H | 1 |
| Fujii, C | 1 |
| Miyashita, K | 1 |
| Mitsuishi, M | 1 |
| Sato, M | 1 |
| Fujii, K | 1 |
| Inoue, H | 1 |
| Hagiwara, A | 1 |
| Endo, S | 1 |
| Uto, A | 1 |
| Ryuzaki, M | 1 |
| Nakajima, M | 1 |
| Tanaka, T | 1 |
| Tamaki, M | 1 |
| Muraki, A | 1 |
| Kawai, T | 1 |
| Itoh, H | 1 |
1 trial available for aminolevulinic acid and Sarcopenia
| Article | Year |
|---|---|
Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study).
Topics: Aged; Aminolevulinic Acid; Animals; Hand Strength; Humans; Iron; Mice; Muscle Strength; Muscle, Skel | 2023 |
1 other study available for aminolevulinic acid and Sarcopenia
| Article | Year |
|---|---|
Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Electron Transport | 2017 |